COVID-19 : efforts to increase vaccine availability and perspectives on initial implementation: report to congressional addressees.

Format:

Book

Government document

Author/Creator:

United States. Government Accountability Office, author.

Language:

English

Subjects (All):

COVID-19 (Disease)--Vaccination--United States.

COVID-19 (Disease).

COVID-19 (Disease)--Treatment--United States.

Vaccination--United States--Planning.

Vaccination.

Vaccination--Government policy--United States.

Public health administration--United States.

Public health administration.

Emergency management--Evaluation.

United States.

Physical Description:

1 online resource (ii, 48 pages) : illustrations

Other Title:

Efforts to increase vaccine availability and perspectives on initial implementation

Place of Publication:

Washington, DC : United States Government Accountability Office, 2021.

Summary:

Providing the public with safe and effective vaccines to prevent COVID-19 is crucial to mitigating the public health and economic impacts of the disease. The U.S. had almost 30 million reported cases and over 545,000 reported deaths as of March 27, 2021. The federal government took a critical step in December 2020 in authorizing the first two COVID-19 vaccines and beginning distribution of doses across the nation. The government had distributed about 180.6 million vaccine doses, and about 147.8 million doses had been administered, as of March 27, 2021, according to Centers for Disease Control and Prevention (CDC) data. This report examines, among other issues, actions the federal government has taken to increase the availability of COVID-19 vaccine doses, and challenges with initial vaccine implementation--that is, prioritizing, allocating, distributing, and, and administering vaccine doses--identified by stakeholders and steps the federal government has taken to improve vaccine implementation.

Contents:

Background.

The federal government's contracting approach aimed to accelerate vaccine development and manufacturing while mitigating cost risk to the government.

The Federal Government has purchased additional vaccine doses and helped mitigate manufacturing challenges to increase vaccine availability.

Stakeholders identified challenges with initial COVID-19 vaccination; the Federal Government has taken some steps to help improve vaccine implementation.

Agency comments.

Appendices.

Notes:

"April 2021."

"GAO-21-443."

Includes bibliographical references.

Online resource; title from cover (GAO, viewed on January 25, 2022).

OCLC:

1274035214